[go: up one dir, main page]

MX2018011425A - Construcciones de anticuerpos de adn y método para utilizarlas. - Google Patents

Construcciones de anticuerpos de adn y método para utilizarlas.

Info

Publication number
MX2018011425A
MX2018011425A MX2018011425A MX2018011425A MX2018011425A MX 2018011425 A MX2018011425 A MX 2018011425A MX 2018011425 A MX2018011425 A MX 2018011425A MX 2018011425 A MX2018011425 A MX 2018011425A MX 2018011425 A MX2018011425 A MX 2018011425A
Authority
MX
Mexico
Prior art keywords
constructions
dna antibodies
combination
nucleic acid
acid sequence
Prior art date
Application number
MX2018011425A
Other languages
English (en)
Inventor
B Weiner David
Yan Jian
Muthumani Karuppiah
Flingai Seleeke
Sardesai Niranjan
Elliott Sarah
Patel Ami
Original Assignee
B Weiner David
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by B Weiner David filed Critical B Weiner David
Publication of MX2018011425A publication Critical patent/MX2018011425A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C07K16/116—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En la presente, se describe una composicion que comprende la combinacion de una secuencia de acido nucleico que codifica un polinucleotido deseado que provoca una respuesta inmunitaria en un mamifero y una secuencia de acido nucleico que codifica un anticuerpo, un fragmento de este, una variante de este, o una combinacion de estos.
MX2018011425A 2016-03-21 2017-03-21 Construcciones de anticuerpos de adn y método para utilizarlas. MX2018011425A (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662311316P 2016-03-21 2016-03-21
US201662332381P 2016-05-05 2016-05-05
US201662376162P 2016-08-17 2016-08-17
US201662396748P 2016-09-19 2016-09-19
US201662396750P 2016-09-19 2016-09-19
US201662417093P 2016-11-03 2016-11-03
US201662429454P 2016-12-02 2016-12-02
US201662429473P 2016-12-02 2016-12-02
PCT/US2017/023479 WO2017165460A1 (en) 2016-03-21 2017-03-29 Dna antibody constructs and method of using same

Publications (1)

Publication Number Publication Date
MX2018011425A true MX2018011425A (es) 2019-09-04

Family

ID=59900715

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011425A MX2018011425A (es) 2016-03-21 2017-03-21 Construcciones de anticuerpos de adn y método para utilizarlas.

Country Status (11)

Country Link
US (1) US20190091322A1 (es)
EP (1) EP3432918A4 (es)
JP (2) JP2019509350A (es)
KR (2) KR20230012070A (es)
CN (1) CN109890407A (es)
AU (2) AU2017238168B2 (es)
BR (1) BR112018069297A2 (es)
CA (1) CA3018566A1 (es)
MX (1) MX2018011425A (es)
SG (2) SG11201808152PA (es)
WO (1) WO2017165460A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110075287A (zh) * 2013-03-15 2019-08-02 宾夕法尼亚大学理事会 用于结核病的预防或治疗的合成免疫原
US10087240B2 (en) * 2013-12-13 2018-10-02 Inovio Pharmaceuticals, Inc. DNA antibody constructs and method of using same
KR20240155978A (ko) * 2016-05-05 2024-10-29 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 인플루엔자 바이러스를 표적으로 하는 dna 단일 클론 항체
RU2752562C2 (ru) * 2016-09-14 2021-07-29 Эббви Байотерапьютикс Инк. Антитела к pd-1(cd279)
KR20240090525A (ko) * 2016-09-19 2024-06-21 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 지카바이러스에 대항하는 신규한 백신 및 지카바이러스에 대해 사용하기 위한 dna 항체 작제물의 조합
US20190284261A1 (en) * 2016-11-07 2019-09-19 The Trustees Of The University Of Pennsylvania Dna antibody constructs for use against lyme disease
KR20190114963A (ko) * 2016-12-02 2019-10-10 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 에볼라 바이러스에 대한 사용을 위한 dna 항체 작제물
WO2019139648A2 (en) * 2017-09-15 2019-07-18 David Weiner Dna antibody constructs for use against ebola virus
US12194086B2 (en) 2017-10-12 2025-01-14 The Wistar Institute Of Anatomy And Biology Mayaro virus consensus antigens, DNA antibody constructs for use against Mayaro virus, and combinations thereof
WO2019075300A2 (en) * 2017-10-12 2019-04-18 The Wistar Institute Of Anatomy And Biology ANTIGENS MAYARO VIRUS CONSENSUS, DNA TYPE ANTIBODY CONSTRUCTS FOR USE AGAINST THE MAYARO VIRUS, AND THEIR COMBINATIONS
WO2019152603A1 (en) * 2018-01-31 2019-08-08 The Wistar Institute Of Anatomy And Biology Nucleic acid antibody constructs for use against zika virus
US20210047388A1 (en) * 2018-01-31 2021-02-18 The Wistar Institute Of Anatomy And Biology Nucleic acid antibody constructs for use against ebola virus
WO2019152599A1 (en) * 2018-01-31 2019-08-08 The Wistar Institute Of Anatomy And Biology Nucleic acid monoclonal antibodies targeting pcsk9 and methods of use
US12466862B2 (en) * 2019-06-04 2025-11-11 Arizona Board Of Regents On Behalf Of Arizona State University Plant-produced mABs against chikungunya virus with enhanced effector function and efficacy
US20230203133A1 (en) * 2020-05-07 2023-06-29 The Wistar Institute Of Anatomy And Biology Dna antibody constructs for use against hepatitis b virus
WO2021252519A1 (en) * 2020-06-08 2021-12-16 University Of Florida Research Foundation, Inc. Materials and methods for the diagnosis and treatment of cancer
WO2023183818A2 (en) * 2022-03-21 2023-09-28 University Of Georgia Research Foundation, Inc. A novel h1n1 antibody

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606425D0 (en) * 1996-03-27 1996-06-05 Binding Site Ltd Improvements in and relating to the production of antibodies and test kits incorporating antibodies
CN1480215A (zh) * 2003-07-07 2004-03-10 叶新新 Sars病毒抗原抗体复合疫苗及实验动物模型与方法
CN107083391A (zh) * 2008-04-04 2017-08-22 宾夕法尼亚大学托管会 屈曲病毒蛋白共有序列、编码该屈曲病毒蛋白共有序列的核酸分子和组合物及其使用方法
US20110045534A1 (en) * 2009-08-20 2011-02-24 Cell Signaling Technology, Inc. Nucleic Acid Cassette For Producing Recombinant Antibodies
KR102011026B1 (ko) * 2010-11-12 2019-08-14 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 공통 전립선 항원, 이것을 암호화하는 핵산 분자, 그리고 이것을 포함하는 백신 및 용도
HK1213481A1 (zh) * 2012-12-13 2016-07-08 The Trustees Of The University Of Pennsylvania Dna抗体构建体及其使用方法
US10087240B2 (en) * 2013-12-13 2018-10-02 Inovio Pharmaceuticals, Inc. DNA antibody constructs and method of using same

Also Published As

Publication number Publication date
AU2017238168A1 (en) 2018-10-18
KR20230012070A (ko) 2023-01-25
AU2017238168B2 (en) 2024-06-13
WO2017165460A1 (en) 2017-09-28
SG10202009182RA (en) 2020-11-27
SG11201808152PA (en) 2018-10-30
BR112018069297A2 (pt) 2019-01-22
EP3432918A4 (en) 2020-02-12
EP3432918A1 (en) 2019-01-30
JP2019509350A (ja) 2019-04-04
US20190091322A1 (en) 2019-03-28
CA3018566A1 (en) 2017-09-28
KR20180138204A (ko) 2018-12-28
AU2024203391A1 (en) 2024-06-13
JP2022121440A (ja) 2022-08-19
WO2017165460A9 (en) 2017-11-09
CN109890407A (zh) 2019-06-14

Similar Documents

Publication Publication Date Title
MX2018011425A (es) Construcciones de anticuerpos de adn y método para utilizarlas.
CY1123642T1 (el) Αντισωματα enanti-pd-1
UY40829A (es) Anticuerpos anti-phf-tau y sus usos
CL2021001179A1 (es) Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596).
CY1124806T1 (el) Αντισωματα enanti-cd40 και χρησεις αυτων
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
SV2018005684A (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
MX2017001401A (es) Constructos de anticuerpos de cadena sencilla biespecifica especificos para especies cruzadas optimizadas.
MX2024008202A (es) Anticuerpos anti-c1s y metodos de uso de los mismos.
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
MX2022001085A (es) Anticuerpos anti-c1s humanizados y metodos para usarlos.
MX2018013520A (es) Anticuerpos monoclonales de adn dirigidos a moléculas de punto de control.
MX2024000118A (es) Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
CL2020001137A1 (es) Anticuerpos anti-apoc3 y métodos de uso de estos.
ECSP19008417A (es) Anticuerpos con inmunogenicidad baja y usos de estos
MX2025009846A (es) Composiciones que comprenden moleculas de acido nucleico que codifican anticuerpos sinteticos anti-il-6 y anti-cd126
EA201892124A1 (ru) Днк-конструкции антител и способы их применения